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Abstract: Consumption of cruciferous vegetables is associated with a decreased risk of developing prostate cancer. 
Antineoplastic effects of cruciferous vegetables are attributable to bioactive indoles, most prominently, 3, 3’-diin-
dolylmethane (DIM). In addition to effects on proliferation and apoptosis, DIM acts as an antiandrogen in prostate 
cancer cell lines. This study characterized the effects of prostatic DIM on the androgen receptor (AR) in patients with 
prostate cancer. Men with localized prostate cancer were treated with a specially formulated DIM capsule designed 
for enhanced bioavailability (BR-DIM) at a dose of 225 mg orally twice daily for a minimum of 14 days. DIM levels 
and AR activity were assessed at the time of prostatectomy. Out of 28 evaluable patients, 26 (93%) had detectable 
prostatic DIM levels, with a mean concentration of 14.2 ng/gm. The mean DIM plasma level on BR-DIM therapy 
was 9.0 ng/mL; levels were undetectable at baseline and in follow-up samples. AR localization in the prostate was 
assessed with immunohistochemistry. After BR-DIM therapy, 96% of patients exhibited exclusion of the AR from 
the cell nucleus. In contrast, in prostate biopsy samples obtained prior to BR-DIM therapy, no patient exhibited AR 
nuclear exclusion. Declines in PSA were observed in a majority of patients (71%). Compliance was excellent and 
toxicity was minimal. In summary, BR-DIM treatment resulted in reliable prostatic DIM levels and anti-androgenic 
biologic effects at well tolerated doses. These results support further investigation of BR-DIM as a chemopreventive 
and therapeutic agent in prostate cancer.
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Introduction
Prostate cancer is the most common cancer 
diagnosis and the second leading cause of can-
cer death for men in the United States [1]. 
Dietary factors have emerged as one potential 
modifiable prostate cancer risk factor [2]. In 
particular, consumption of cruciferous vegeta-
bles, such as broccoli, Brussels sprouts, and 
cauliflower, is associated with decreased can-
cer incidence [3, 4]. High dietary intake of cruci-
ferous vegetables has been associated with 
reduced prostate cancer risk [5] and less ag- 
gressive disease at presentation [6]. Two major 
bioactive compounds in cruciferous vegetables 
are indole-3-carbinol (I3C) and 3, 3’-diindolyl-
methane (DIM). I3C is converted to its dimeric 
derivative, DIM, during cooking. When added in 
vitro to cell culture media, I3C spontaneously 
dimerizes, forming DIM in a quantitative and 
time-dependent fashion [7]. These two indoles 
have multiple potentially therapeutic effects 
when studied in vitro. I3C and DIM administra-
tion have anti-proliferative and pro-apoptotic 
effects in several tumor cell lines [8-10]. I3C 
and DIM inhibit cell growth, induce G1 cell-cycle 
arrest, and promote apoptosis in androgen-
independent and androgen-dependent pros-
tate cancer cells [11-16].
Diverse molecular mechanisms appear to be 
responsible for these biological effects, but an 
intriguing finding in prostate cancer is that DIM 
functions as an androgen receptor (AR) antago-
nist [11]. DIM down-regulates expression of the 
AR [17] and prevents AR translocation to the 
nucleus [11]. As a consequence, DIM treatment 
leads to decreased transcription of androgen 
receptor target genes such as PSA. Furthermore, 
DIM exhibits no AR agonist activity. When evalu-
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ated in pre-clinical models, DIM has been sh- 
own to have therapeutic effect in flank and 
metastatic murine prostate cancer models [14, 
17].
Nutritional grade absorption-enhanced DIM 
(BR-DIM) is a dietary supplement that contains 
pharmaceutically pure DIM, microdispersed in 
spray-dried starch particles. Previous human 
studies with BR-DIM have reported minimal tox-
icity [18-20]. We have previously completed a 
phase I clinical trial of BR-DIM in patients wi- 
th non-metastatic, hormone-refractory prosta- 
te cancer with rising serum PSA [19]. The rec-
ommended phase II dose based on toxicity and 
pharmacokinetic data was 225 mg orally twice 
daily. Armed with the appropriate dose and 
schedule, we proceeded with a phase II clinical 
trial in patients with prostate cancer. BR-DIM 
was administered to patients prior to radical 
prostatectomy (RP) with the primary objective 
of measuring DIM levels in prostate tissue and 
in plasma. We hypothesized that BR-DIM ad- 
ministration in prostate cancer patients would 
lead to the accumulation of DIM in the prostate 
tissue. Further, this study allowed us to test 
whether prostatic DIM would act as an anti-
androgen in a clinical setting.
Material and methods
Study design and conduct
The review boards of both participating institu-
tions (Wayne State University and Henry Ford 
Health System) approved the study. The study 
was conducted according to the provisions of 
the Declaration of Helsinki and the Good Clini- 
cal Practice Guidelines of the International Con- 
ference on Harmonization. All patients provided 
written informed consent prior to participation 
in the study.
The study was designed and the protocol was 
written by the senior academic authors. The 
first draft of the manuscript was written by the 
first author, and the manuscript was then com-
pleted and approved by all the authors. All the 
authors were responsible for writing the manu-
script and for the decision to submit the manu-
script for publication, and all the authors as- 
sume responsibility for the completeness and 
integrity of the data and the fidelity of the study 
to the protocol and analysis plan (see supple-
mental information for full protocol). All the 
authors or authors’ institutions had agreeme- 
nts with the lead investigational site regarding 
confidentiality of the data. No one who is not an 
author contributed to the writing of the manu-
script. The protocol was registered on the NIH 
clinical trials database prior to the enrollment 
of any patients (http://clinicaltrials.gov/show/
NCT00888654).
Study participants
Patients were eligible for enrollment if they had 
a histologically or cytologically confirmed diag-
nosis of treatment-naïve prostate cancer, with 
clinical T1 or T2 disease, and suitable for pros-
tatectomy according to the clinical judgment 
of their surgeon. Patients were required to ha- 
ve adequate hematologic, hepatic, and renal 
function, with an ECOG performance status of 
≤ 2. Patients were not permitted to take any 
other antineoplastic agents, micronutrient sup-
plements or dietary soy products while enroll- 
ed on study. Concomitant treatment with kno- 
wn P450 inducers and inhibitors (e.g. carbam-
azepine, clarithromycin, fluconazole, fospheny- 
toin, itraconazole, ketoconazole, phenobarbi-
tal, phenytoin, rifabutin, and rifampin) with po- 
tential to interfere with the metabolism of 
BR-DIM was not allowed. In addition, no andro-
gen deprivation therapy, including the use of 
5-alpha-reductase inhibitors, was allowed on 
study. Patients with serious and uncontrolled 
acute or chronic medical or psychiatric condi-
tions were not eligible. A complete list of inclu-
sion and exclusion criteria is provided in the 
protocol (Supplementary Information).
Study treatment and evaluation
Prior to planned prostatectomy, eligible and 
consenting subjects were prescribed BR-DIM 
(BioResponse, LLC, Boulder, CO) at a dose of 
225 mg orally twice daily for a minimum of 14 
days and up to 72 days (depending on surgical 
scheduling). Each 75 mg BR-DIM capsule was 
produced following Good Manufacturing Prac- 
tice (GMP) regulations, which include in-pro-
cess testing for DIM and post-production assay 
for DIM content using an HPLC method per-
formed by independent analytic laboratory. Pa- 
tients were instructed to take 3 tablets twice 
daily with 8 ounces of water, with or without 
food. The last dose of study drug was to be 
taken on the evening before surgery. If surgery 
was delayed beyond 72 days from the BR-DIM 
treatment start date, BR-DIM was discontin-
ued. Otherwise, BR-DIM treatment continued 
Pre-prostatectomy effects of BR-DIM
168 Am J Transl Res 2016;8(1):166-176
until either surgery or one of the following ev- 
ents: disease progression, intercurrent illness 
which precluded further treatment, unaccept-
able toxicity (defined as CTCAE version 3.0 
grade 3 or higher toxicity), or patient or investi-
gator request. No dose modification was allo- 
wed. Eligible patients were evaluable if they 
had at least 14 days of BR-DIM treatment. 
Eligible, evaluable patients were compliant if 
they took at least 80% of the first 14 days of 
intended BR-DIM treatment based on pill count.
Pharmacokinetic and pharmacodynamic 
measures
Blood samples for DIM levels were collected 
before starting BR-DIM treatment, immediately 
prior to surgery, and during routine follow-up 
within the first 24 months after prostatectomy. 
Within 1 hour of collection in heparin anticoag-
ulant tubes, blood samples were centrifuged at 
25°C at 3000 rpm for 10 minutes. Plasma was 
immediately transferred to cryogenic tubes in 
two aliquots and kept at -80°C until analysis. 
DIM concentration in human plasma was mea-
sured using a validated high-performance liq-
uid chromatographic method with tandem ma- 
ss spectrometric (LC-MS/MS) detection as pre-
viously described [19]. DIM levels were also 
measured in prostate tissue. Approximately 
250-500 mg of fresh tissue specimen from the 
prostatectomy (benign prostate) was collected 
and stored at -80°C until analysis. DIM concen-
tration in the prostate was determined using a 
validated LC-MS/MS method. Serum PSA and 
testosterone levels were taken at the same 
time as DIM samples (pre-treatment, pre-sur-
gery, and post-surgery) and processed in the 
clinical laboratory according to usual procedu- 
res.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissues we- 
re processed for immunohistochemical analy-
sis as follows. Deparaffinized sections were 
stained manually using the avidin-biotin-com-
plex technique. Four micron tissue sections 
were cut from the selected tumor blocks on 
charged slides and stained for immunohisto-
chemical analysis using specific antibodies for 
Androgen Receptor (Monoclonal Mouse Anti- 
Human Clone AR441, Dako Carpinteria, CA; Co- 
de # M3562) using the polymer based detec-
tion system. Standard staining protocols accor- 
ding to the laboratory manual and the manufac-
turer’s suggested specimen preparation and 
staining conditions were used in the Autostainer 
(Dako Link 48). All reagents used in the staining 
process on the autostainer were supplied in 
EnVision FLEX+, Mouse, High pH, (Link) kit 
(Dako code #K8002). The protocol was then 
optimized for antigen retrieval, antibody dilu-
tion and incubation conditions. A known posi-
tive tissue was stained with each investigative 
case study. Briefly, after deparaffinizing and 
hydrating to phosphate-buffered saline buffer 
(pH 7.4), the sections were pretreated with 
hydrogen peroxide (3%) for 5 minutes to remove 
endogenous peroxidase. Primary antibody was 
then applied, AR 1:75 for 20 minutes, followed 
by washing and incubation with FLEX+ Mouse 
(Linker) for 15 minutes. After buffer rinse it was 
incubated with FLEX/HRP for 20 minutes. Su- 
bsequent buffer rinse was followed by FLEX+ 
DAB+ Substrate- Chromogen for 10 minutes 
and counterstained with Mayer hematoxylin fol-
lowed by dehydration and mounting. Immuno- 
stained samples were reviewed by a genitouri-
nary pathologist who evaluated staining inten-
sity and percent positively-stained cells. The AR 
staining score was the product of these two 
numbers.
Statistical methods
The study design was a 1-stage, 1-sample 
Phase 2 clinical trial, enrolling patients from 2 
institutions. The primary objective was to mea-
sure the level of DIM in prostate tissue after 
treatment of prostate cancer patients with oral 
BR-DIM at 225 mg twice daily for a minimum of 
14 days. The primary statistical endpoint was 
the mean level of DIM in prostate tissue after 
treatment with BR-DIM. It was desired to esti-
mate the mean level of DIM in prostate tissue 
after treatment with BR-DIM to within 1/3 of a 
standard deviation (SD) unit, with 90% confi-
dence. This level of precision in the estimation 
of the mean DIM level in post-treatment pros-
tate tissue required N=27 patients (as deter-
mined via PASS 2011 software). These 27 
patients were to be eligible, evaluable, and 
compliant (as defined above).
Standard descriptive statistics were used to 
summarize demographic and clinical variables, 
as well as the plasma and prostate tissue DIM 
levels. Point and 90% confidence interval (CI) 
estimates of the mean plasma and prostate tis-
sue DIM levels were calculated. Due to sub-
stantial non-normality in the distributions of 
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prostate tissue DIM level, plasma DIM level, 
and length of BR-DIM treatment, nonparamet-
ric methods of statistical analysis were used, 
including Spearman rank correlation coeffici- 
ents. To explore the relationship of prostate tis-
sue DIM level to plasma DIM level we used a 
nonparametric regression approach. We fit a 
locally estimated scatterplot smoother (LOESS) 
curve to that bivariate relationship using the 
LOESS procedure in SAS 9.3 software. A LOESS 
curve was also fit to the bivariate relationship 
of prostate tissue DIM level and length of 
BR-DIM treatment. The default smoothing 
parameter (percent of the total observations 
used in each smoothing neighborhood) was 
used in the LOESS procedure. These nonpara-
metric LOESS curves better described the non-
linear character of those two relationships.
Results
Patient characteristics
A total of 41 prostate cancer patients with 
plans for prostatectomy were recruited from 
two institutions. One patient was deemed ineli-
gible due to a disallowed concomitant medica-
tion yielding a total of 40 eligible patients. 
Patient recruitment was comparable between 
the two institutions (23 vs. 17 eligible patients). 
Baseline characteristics of the 40 eligible pa- 
tients are presented in Table 1. The median 
age was 58 years (range, 40-76). The majority 
of patients were Caucasian (55%) and 40% of 
patients were African American. The significant 
African American population reflects the demo-
graphics of prostate cancer patients at the two 
Table 1. Patient characteristics
Characteristic Eligible patients N=40
Evaluable patients 
N=28
Age in years-Median (range) 58 (40-76) 59 (50-73)
Race-N (%) European American 22 (55%) 16 (57%)
African American 16 (40%) 11 (39%)
Middle Eastern 1 (3%) 0 (0%)
Other 1 (3%) 1 (4%)
Performance status-N (%) ECOG 0 40 (100%) 28 (100%)
Pre-treatment PSA (ng/mL)-Median (range) 6.4 (2.1-29.4) 6.4 (2.1-20.5)
Testosterone (ng/mL)-Median (range) 301 (77-608) 292 (77-557)
Gleason sum from biopsy-N (%) 6 17 (44%) 11 (39%)
7 21 (53%) 16 (57%)
≥ 8 2 (5%) 1 (4%)
Clinical T stage-N (%) T1c 30 (75%) 20 (71%)
T2a 5 (13%) 3 (11%)
T2b 3 (8%) 3 (11%)
T2c 2 (5%) 2 (7%)
Clinical N stage-N (%) N0 11 (28%) 8 (29%)
NX 29 (73%) 20 (71%)
Gleason sum from surgical specimen-N (%) 6 11 (28%) 7 (25%)
7 26 (65%) 20 (71 %)
≥ 8 2 (5%) 1 (4%)
unknown 1 (3%) 0 (0%)
Pathologic T stage-N (%) T2a 2 (5%) 1 (4%)
T2c 23 (58%) 16 (57%)
T3a 10 (25%) 8 (29%)
T3b 4 (10%) 3 (11%)
TX 1 (3%) 0 (0%)
Pathologic N stage-N (%) N0 33 (85%) 24 (86%)
NX 7 (18%) 4 (14%)
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institutions. All enrolled patients had excellent 
performance status (ECOG 0). The median pre-
treatment PSA was 6.4 ng/mL (range, 2.1-29.4 
ng/mL). The median baseline testosterone lev- 
el was 301 ng/mL (range, 77-608). Nearly all 
patients (95%) had Gleason sum of 6 or 7 on 
pre-prostatectomy biopsy. Seventy-five percent 
of patients had clinical stage T1c prostate can-
cer; no patients had clinically apparent lymph 
node metastases.
Surgical findings are reported for the 39 pa- 
tients for whom data was available (Table 1). At 
the time of resection, most patients were found 
to have Gleason 6 or 7 disease (28% and 67%, 
respectively). Disease was confined to the pros-
tate (pT2) in 64% of patients. Extraprostatic 
extension or seminal vesicle invasion (pT3) was 
seen in 14 patients (36%).
Treatment and compliance
Eligible patients were instructed to take 225 
mg (3 × 75 mg capsules) of BR-DIM twice daily 
until the evening before planned prostatecto-
my. The median length of treatment on BR-DIM 
was 19 days (range 4-104). The planned dura-
tion of treatment was specified to be between 
14 and 72 days, depending on the timing of sur-
gery. Patients were deemed not evaluable for 
the primary endpoint if the length of BR-DIM 
treatment duration was outside the protocol-
defined 14-72 day pre-prostatectomy window. 
A change in surgery date caused the duration 
of BR-DIM treatment to fall outside of the 14-72 
day window for five patients. Prostatectomy 
was cancelled for one patient because of adhe-
sions found at the time of surgery. Treatment 
duration was less than 14 days for two patien- 
ts who withdrew from the study, and for one 
patient who discontinued therapy because of 
toxicity. Three patients did not have evaluable 
clinical samples for biomarker analyses on the 
day of prostatectomy. In summary, a total of 28 
patients were evaluable for the primary end-
point of DIM levels in the prostate (Figure 1).
In addition to duration of treatment with BR- 
DIM, compliance was assessed to ensure ade-
quate BR-DIM exposure. Compliance was mea-
sured with pill diaries and by comparing actual 
to expected returned pill counts. Median com-
pliance by patient diary was 100% of intended 
BR-DIM treatment for all registered patients 
(range 0-100%). In the subset of 28 evaluable 
patients, compliance by patient diary ranged 
from 96-100% of intended treatment, render-
ing all evaluable patients compliant with thera-
py. Median compliance as measured by pill 
count was 95% for all 37 patients who were 
dispensed BR-DIM tablets (range 0-217%). In 
the 28 evaluable patients, compliance by pill 
Figure 1. Patient disposition. Out of 41 patients who enrolled, 36 patients started protocol therapy. A total of 28 
patients were evaluable for the primary endpoint of DIM levels in the prostate.
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count ranged from 80-217% of intended treat-
ment, with a median value of 96%.
were detectable in the prostate for 26 of 28 
patients (92.9%). The median DIM level in the 
Table 2. Pre- and post-treatment measures among the 28 evaluable patients
Characteristic N Median Mean
90% confidence limits
SDa Minimum Maximum
Lower Upper
Plasma PSA pre-treatment (ng/mL) 28 6.4 7.2 5.8 8.6 4.3 50.0 73.0
Plasma PSA post-treatment (ng/mL) 23 5.9 6.8 5.5 8.1 3.6 2.6 18.0
Plasma PSA difference (ng/mL) 23 -0.6 -1.0 -2.0 0.0 2.7 -8.1 5.3
Plasma DIM pre-treatment (ng/mL) 27 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Plasma DIM post-treatment (ng/mL) 28 7.5 9.0 6.8 11.3 6.9 0.0 24.7
Prostate tissue DIM post-treatment (ng/gm) 28 11.6 14.2 10.6 17.7 11.1 0.0 50.1
aStandard deviation.
Figure 2. Prostatic DIM measurements. A. After a minimum of 14 days of 
BR-DIM therapy, DIM levels were measured in the plasma and at the time 
of prostatectomy. Prostate DIM levels are plotted against plasma DIM 
levels for each evaluable patient. The nonparametric regression LOESS 
curve is plotted, with the shaded area indicating the 90% confidence 
limits for the predicted mean prostate tissue DIM level. B. Prostate DIM 
levels are plotted against length of BR-DIM treatment for each evaluable 
patient. The nonparametric regression LOESS curve is plotted, with the 
shaded area indicating the 90% confidence limits for the predicted mean 
prostate tissue DIM level.
Pharmacokinetic and pharmaco-
dynamic measures
Pre- and post-treatment pharma-
cokinetic and pharmacodynamic 
measures are summarized in 
Table 2. Plasma DIM levels were 
measured for each patient prior 
to starting to BR-DIM therapy. No 
patient had detectable DIM lev-
els in the pre-treatment sample. 
Post-treatment DIM levels were 
taken on the morning of surgery, 
approximately twelve hours after 
the last dose of BR-DIM. Post-
treatment DIM levels were avail-
able for all evaluable patients. 
Plasma DIM levels were detect-
able after BR-DIM therapy in all 
but one patient. For evaluable 
patients, the median plasma DIM 
level in the post-treatment sam-
ple was 7.5 ng/mL (range 0-24.7 
ng/mL). The mean plasma DIM 
level on BR-DIM therapy was 9.0 
ng/mL (90% CI: 6.8-11.3 ng/mL). 
Plasma DIM levels were again 
measured during follow-up, typi-
cally at least one month after sur-
gery. Levels of DIM in the plasma 
were undetectable at this time-
point for the subset of patients 
with available data (n=8).
To assess our primary endpoint, 
DIM levels were measured in the 
prostate using a freshly frozen 
prostate sample taken at the 
time of surgery. Prostatic DIM 
levels were available for all 28 
evaluable patients. DIM levels 
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prostate was 11.6 ng/g and the mean DIM con-
centration was 14.2 ng/g (90% CI: 10.6-17.7 
ng/g). Prostatic DIM levels did not correlate 
strongly with plasma DIM levels (Spearman 
rank correlation coefficient 0.53; 90% CI: 0.24-
0.72). The nonparametric regression LOESS 
curve of prostatic DIM levels was increasing 
through about 12 ng/mL of plasma DIM, but 
flat thereafter (Figure 2A). There was virtually 
no relationship between prostatic DIM levels 
and length of therapy (Spearman rank correla-
tion coefficient -0.08; 90% CI: -0.39-0.24), con-
sistent with our previous demonstration that 
systemic steady state levels are achieved after 
one week of BR-DIM therapy [19]. The nonpara-
metric regression LOESS curve of prostatic DIM 
levels was essentially flat through about 30 
days of BR-DIM treatment, and slightly decreas-
ing thereafter (Figure 2B). The mean (median) 
prostatic DIM levels for the six patients who 
took only the minimum amount of BR-DIM ther-
apy (14 days) was 14.0 (10.1) ng/gm, com-
pared to a mean level of 14.2 (13.6) ng/gm for 
the 22 patients who took BR-DIM therapy for > 
14 days (see also Figure 2B).
BR-DIM effects on in vivo androgen receptor 
signaling
Given the effects of DIM on the androgen re- 
ceptor in pre-clinical models, we assessed and- 
rogen receptor staining in prostate samples 
before and after BR-DIM treatment. Pre-BR-
DIM AR staining was performed on pre-therapy 
biopsy specimens while post-BR-DIM AR stain-
ing was performed on specimens taken at the 
time of prostatectomy. Androgen receptor sta-
tus was unknown for 2 patients, yielding 26 
patients evaluable for these analyses. A score 
was assigned to each prostate sample equal to 
the product of staining intensity and percent 
positively-stained cells. The median AR staining 
Figure 3. BR-DIM therapy results in nuclear exclusion of androgen receptor. Prostate specimens were stained for an-
drogen receptor. Representative images from samples taken before (A) and after (B) BR-DIM treatment are shown at 
40X magnification. Vacuoles in the post-BR-DIM treatment group are indicative of nuclear exclusion of the androgen 
receptor. AR staining score and the percentage of cases with nuclear staining of androgen receptor before and after 
BR-DIM therapy are plotted in (C) and (D), respectively.
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score in the 26 pre-BR-DIM specimens was 
300 while the median AR staining score in the 
same 26 post-BR-DIM prostatectomy samples 
was 255. The mean AR staining in the pre-BR-
DIM specimens was 278 (90% CI: 263-293) 
compared to a mean value of 245 (90% CI: 227-
263) in the post-BR-DIM specimens. Staining 
scores suggested decreased protein expres-
sion of the androgen receptor in response to 
therapy.
As a nuclear receptor and transcriptional coact-
ivator, translocation of the androgen receptor 
to the nucleus after ligand binding is an impor-
tant measure of its biologic activity. Immuno- 
histochemical staining for androgen receptor 
comparison, the median plasma testosterone 
level prior to BR-DIM treatment was 280 ng/mL 
(range 77-557 ng/mL). In the 26 patients evalu-
able for androgen receptor staining, plasma 
testosterone levels increased post-BR-DIM th- 
erapy in 15 patients, decreased in six patients 
and were unknown in five patients. The mean 
difference between pre- and post-BR-DIM tes-
tosterone levels was an increase of 76 ng/mL 
(range -107 ng/mL to 359 ng/mL).
In addition to its clinical utility as a tumor mark-
er, prostate-specific antigen (PSA) is an impor-
tant target of AR-dependent transcription. PSA 
levels were assessed both before and after 
therapy with BR-DIM (Table 2). PSA levels 
Figure 4. Waterfall plots of PSA declines. PSA declines are presented in water-
fall format for both absolute (A) and % PSA declines (B).
revealed nuclear exclusion 
in 25 of 26 prostatectomy 
specimens (Figure 3). One 
prostatectomy sample (4%; 
90% CI: 1%-16%) showed nu- 
clear androgen receptor st- 
aining. Androgen receptor st- 
aining was also performed 
on archived prostate biopsy 
samples obtained from the 
patient prior to starting BR- 
DIM therapy. These pre-BR-
DIM prostate biopsy sampl- 
es did not demonstrate nu- 
clear exclusion of androgen 
receptor for any of the 26 
evaluable patients, hence a 
nuclear androgen receptor 
staining rate of 100% (90% 
CI: 91%-100%) (Figure 3). Co- 
mpared to pre-BR-DIM sam-
ples, post-BR-DIM prostate 
cancer samples demonstra- 
ted a striking effect on AR 
nuclear translocation.
Nuclear translocation of an- 
drogen receptor is expected 
in the presence of its ligand, 
testosterone. We therefore 
evaluated testosterone lev-
els before and after BR-DIM 
treatment. Nuclear exclusi- 
on of androgen receptor was 
not dependent upon redu- 
ced circulating levels of tes-
tosterone. The median plas-
ma testosterone level after 
BR-DIM treatment was 387 
ng/mL (range 118-686). In 
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declined in 16 of 23 patients (70%). In 28 
patients, the median PSA level prior to therapy 
was 6.4 ng/mL (range 2.1 ng/mL to 20.5 ng/
mL). In 23 patients, the median PSA level after 
BR-DIM treatment was 5.9 ng/mL (range 2.6 
ng/mL to 18.0 ng/mL). The median change in 
absolute PSA levels of 23 patients was a 0.6 
ng/mL decline (range 8.1 ng/mL decline to 5.3 
ng/mL increase). PSA changes after BR-DIM 
therapy are presented in waterfall plots (Figure 
4).
Adverse events
Patients were deemed evaluable for toxicity 
from their first dose of BR-DIM. Laboratory 
monitoring included glucose, creatinine, sodi-
um, liver function testing and coagulation pa- 
rameters given previous reports of asymptom-
atic laboratory abnormalities in patients treat-
ed with BR-DIM [19]. Overall, BR-DIM was very 
well tolerated. Two patients reported head-
aches (maximal CTCAE grade 3) which were de- 
emed by the investigator to be possibly related 
to BR-DIM therapy. No other toxicity was report-
ed (Table 3).
Discussion
Overall, our results indicate that treatment with 
BR-DIM is associated with biologically signifi-
cant DIM concentrations in the human pros-
tate. After BR-DIM treatment (225 mg orally 
twice daily), we found that prostatic DIM levels 
are reliably detected by fourteen days, and lev-
els do not increase with longer treatment. Th- 
ese findings are consistent with our previous 
reports that steady state levels in the plasma 
are achieved by one week [19]. DIM was not 
detectable in the plasma in any of 8 follow-up 
samples. Toxicity from BR-DIM appears to be 
observed even in the presence of ligand, as 
serum testosterone levels generally were high-
er after BR-DIM therapy. The inability of AR to 
translocate to the nucleus would be expected 
to impact its ability to direct transcription in 
response to ligand signaling. We observed de- 
creases in serum PSA in a majority of patients, 
consistent with a potential effect on AR signal-
ing. Although observed decreases were small, 
treatment duration was quite short (median of 
19 days) and the study was not designed to 
assess changes in PSA as its primary endpoint. 
Clinical guidelines suggest continuing treat-
ment for at least 12 weeks to ensure adequate 
drug exposure when evaluating changes in PSA 
[21].
Attrition rate on this study was higher than 
anticipated from our previous experience in the 
setting of castrate-resistant biochemical recur-
rence, potentially related to the studied surgi-
cal patient population. In contrast to patients 
experiencing cancer recurrence, prostatectomy 
patients being treated with curative intent may 
be less tolerant of toxicity or inconvenience 
from an experimental therapy, even if mild. 
Furthermore, several patients were not evalu-
able because patients chose to change surgi-
cal dates rather than continue on study. Al- 
though attrition is a study limitation, adequate 
numbers of patients were enrolled to evaluate 
our primary endpoint according to the original 
statistical plan.
In summary, treatment with BR-DIM was suc-
cessful in maintaining biologically active levels 
of DIM in the prostate. BR-DIM clearly impacts 
nuclear translocation of the androgen receptor, 
which plays a key role in prostate tumor patho-
genesis. Confirming the anti-androgenic activity 
Table 3. Adverse Event rates among all 36 treated patients
Adverse Event N (%)
90% confi-
dence limits Grade
Lower Upper
Headache 2 (6%) 2% 15% 3
Gastrointestinal toxicity 0 (0%) 0% 7% N/A
Hematologic toxicity 0 (0%) 0% 7% N/A
Hyperglycemia 0 (0%) 0% 7% N/A
Hyponatremia 0 (0%) 0% 7% N/A
Increased creatinine 0 (0%) 0% 7% N/A
Increase in coagulation parameters 0 (0%) 0% 7% N/A
N/A = Not applicable.
minimal, with headache the only re- 
ported side effect.
Prostatic DIM may result in dec- 
reased expression of AR as assessed 
by immunohistochemical staining, 
but more prominent was the near 
universal presence of nuclear vacu-
oles indicating AR nuclear exclusion. 
Inhibition of nuclear translocation 
has also been reported for other 
novel anti-androgens such as enzalu-
tamide and may contribute to the 
anti-neoplastic activity of this class 
of drug. AR nuclear exclusion was 
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of BR-DIM in humans supports the further 
study of this nutraceutical as both a therapeu-
tic and chemopreventive agent.
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